VISOLIS TECHNOLOGIES LTD

Their core work

Visolis Technologies is a UK-based biotech SME specialising in the biological and catalytic production of bio-based chemicals and monomers from renewable feedstocks. Their core technology centres on engineering fermentation pathways — particularly the mevalonate route — to produce isoprene and related five-carbon building blocks at industrial purity. Beyond fermentation alone, they work on hybrid bio-chemocatalytic processes that combine microbial biosynthesis with downstream chemical catalysis to convert residual biomass into marketable bio-monomers and bio-polymers. Their commercial interest lies in replacing petrochemical-derived rubber monomers and polymer precursors with sustainable bio-based equivalents.

What they specialise in

How they've shifted over time

In 2015, Visolis entered H2020 with a tightly scoped feasibility study on bio-based isoprene (Bioprene), focused on a single product and a single biological production route. By 2018, their participation in BioCatPolymers shows a meaningful broadening: the keyword set expands from isoprene alone to mevalonate pathway engineering, bio-monomers, 3-methyl-1,5-pentanediol, and hybrid bio-chemocatalytic cascades. The trajectory is clear — from one target molecule toward a platform chemistry capable of producing multiple bio-based monomers and polymer intermediates from waste biomass.

Visolis is moving from single-molecule isoprene production toward a broader bio-chemical platform targeting polymer precursors from residual biomass, making them an increasingly relevant partner for bio-based materials and circular economy projects.

How they like to work

Visolis started as a project coordinator (Bioprene SME-1 feasibility), demonstrating capacity to define and lead their own innovation agenda. In BioCatPolymers they joined as a specialist participant within a larger multi-country Innovation Action consortium, contributing a specific technological component rather than driving the whole project. With 10 unique partners across 6 countries from just 2 projects, their network density is notably high for an SME of this size, suggesting they are sought-after as a niche technology contributor rather than a passive participant.

Despite only two H2020 projects, Visolis has built connections with 10 distinct consortium partners spanning 6 countries, indicating access to a well-connected European bioeconomy research network. No repeated partner pattern is visible at this sample size, suggesting broad rather than deep existing alliances.

What sets them apart

Visolis occupies a rare niche as an SME that bridges fermentation biotech and downstream chemical catalysis — most partners in bio-based materials projects are either pure biology labs or pure chemistry companies, not both. Their focus on the mevalonate pathway for isoprene and C5 diol production gives them IP-level differentiation in a space otherwise dominated by large chemical firms. For a consortium builder, they represent a commercial-stage SME capable of translating research-scale fermentation results toward market-ready bio-monomers.

Highlights from their portfolio

• BioCatPolymers
  A multi-year Innovation Action (2018–2021) where Visolis contributed hybrid bio-chemocatalytic expertise alongside 10+ partners, representing their most technically ambitious and collaborative H2020 engagement.
• Bioprene
  Visolis coordinated this SME Instrument Phase 1 project in 2015, establishing their founding commercial proposition around bio-based high-purity isoprene — the earliest evidence of their core technology direction.